NewswireToday - /newswire/ -
Charlottesville, VA, United States, 2009/04/23 - Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announces the introduction of the Initiator 2.5 microwave synthesizer.
This new system upgrade is designed to offer fast and scalable reactions and has been tailored for synthetic chemistry.
The Initiator 2.5 from Biotage offers increased heating performance, system guided run set-up and improved data management. The Biotage Initiator 2.5 system features 400 watts of power to deliver the most precise heating control of any microwave synthesis instrument on the market. Unlike other microwave synthesizers the new Initiator 2.5 allows chemists to easily share methods and results either through a USB port or network. With a built-in computer and intuitive software that automatically converts conventional parameters to microwave conditions the Initiator 2.5 is the easiest and safest microwave synthesizer available.
With improved heating performance and reaction time, Biotage’s Initiator 2.5 offers increased run time. The system is capable of heating a single sample for up to 96 hours compared with traditional systems that offer a maximum of 24 hours heating time. The unique Initiator system is built on a reliable and robust platform that provides minimal downtime. In addition, the system is easy-to-use with a Wizard that guides new users through the programming of the instrument. Additionally the Initiator offers total automation with an 8-position and 60-position robot for rapid optimization of reaction conditions and analog synthesis. The initiator offers the ability to use both large and small vials to facilitate the scale-up of compounds of interest.
The Initiator 2.5 system also includes a number of features increasing options for data management and connectivity, including the addition of a USB port at the front of the system, Post-Script printer capabilities, integration with Electronic Laboratory Notebooks and easy e-mailing of results.
For more information on the Initiator 2.5, please email product_info[.]biotage.com.
Biotage (biotage.com) is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company’s products to integrated solutions and producing such products, and the Company’s ability to identify and develop new products and to differentiate its products from competitors.